FDA-approved CAR-T cell therapy for non-Hodgkin lymphoma

The U.S. Food & Drug Administration (FDA) recently approved a new form of CAR-T cell therapy for for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. This is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).

City of Hope is one of the first medical centers in the nation to provide this therapy, axicabtagene ciloleucel (also known by the brand name Yescarta), for adult patients with refractory aggressive non-Hodgkin lymphoma.

Axicabtagene ciloleucel targets the antigen CD19, a protein found on the cell surface of NHL as well as other lymphomas and leukemias.

In addition to being one of the only centers in the nation to offer this new FDA-approved therapy, City of Hope has the expertise, knowledge and specialized staff to successfully deliver axicabtagene ciloleucel to patients while continuing to develop additional CAR-T therapies to save even more lives.

City of Hope has long been involved with axicabtagene ciloleucel, supporting its development with data from the ZUMA-1 phase 1 and phase 2 trials, for which City of Hope was a trial center.
  • Physicians who need to refer an NHL patient for treatment should contact: 626-218-2405
  • Patients with refractory aggressive non-Hodgkin lymphoma who think they might be a candidate for this new treatment can contact: 800-934-5555
     

About Non-Hodgkin Lymphoma
  • Lymphoma is the most common form of blood cancer, with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) being the two main forms. NHL is a type of blood cancer that includes multiple different subtypes, all originating in the lymphatic system.
  • Non-Hodgkin lymphoma is one of the most common cancers in the United States, accounting for about four percent of all cancers.  
  • Approximately 72,240 people (adults and children) will be diagnosed with non-Hodgkin lymphoma in 2017 .
  • Sixty percent of all NHL cases in the United States are aggressive NHL, with the most common subtype being diffuse large B-cell lymphoma (DLBCL).
  • Refractory aggressive non-Hodgkin lymphomas grow quickly.